SPECIFIC CLINICAL COURSE OF ACUTE CORONARY SYNDROME IN YOUNG PEOPLE
DOI:
https://doi.org/10.17605/OSF.IO/TJXPYKeywords:
decompensation, hypoperfusion, levosimendan, cardiovascular thrombosisAbstract
Acute coronary syndrome is a serious life-threatening condition that often serves as the clinical debut of ischemic heart disease. In 20-25% of cases, angina pectoris begins with acute myocardial infarction and painful angina after acute myocardial infarction The high incidence of acute coronary syndrome in young people in recent years indicates that the disease is getting younger. From the point of view of modern knowledge, which is the gold standard in the treatment of acute coronary syndrome - modern pharmacological support is very important both before endovascular surgery and during percutaneous intervention.
Downloads
References
Aroney CN, Aylward P, Kelly AM, Chew DPB, Clune E, on behalf of the Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006;184:S9-S29.
Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N EnglJMed 2004 Sep 9;351(11):1097-105.
Bassand JP, Hamm CW, Ardissino D, Boersma E, BudajA, Fernandez- AvilesF, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-1660.
Bhatia R.S., Tu J.V., Lee D.S. et al. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study. N Engl J Med. July 20, 2006;355:260-9
Person H, linder-Klingsell, Eriksson SV et al. Heart failure after myocardial infarction: the importance of diastolic function. Eur Heart J 1995; 16:496-505
Norhammar A,TenerzÂ,Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 2002; 359:2140-2144
Pataricza J., Hohn J., Petri A. et al Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000; 52:213-217.
Pyorala K, Lehto S, De Bacquer D, et aL on behalf of the EURO ASPIRE I and II Group. Risk factor management in diabetic and non-diabetic coronary heart disease patients. Findings from heart disease patients from EURO ASPIRE I and II surveys. Diabetologia 2004;47; 1257-65
Remme WJ, McMurray JJ, Rauch B, et al. Public awareness of heart failure in Europe: first results from SHAPE. European Heart Journal 2005; 26(22) :2413- 21.
Roland Prondzinsky, Henning Lemm, Michael Swyter, Nicholas Wegener, Susanne Unverzagt, Justin M Carter, Axel Schlitt, Ute Buerke, Martin Russ, Karl Werdan, and MchaelBuerke Prognostic markers in Myocardial Infarction complicated by Cardiogenic Shock Circulation, Oct 2007; 116: n_939.
Sadowski M. J.,Pankiewicz J.,Scholtzova H.et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach,for Alzheimer's disease. ProcNatlAcadSci.U S A. 2006:103:18787-92.
Sarnak MJ, Levey AS, Schoolwerth AC,; et al. Kidney disease as a risk factor for development of; cardiovascular disease: a statement from the American: Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research; Clinical Cardiology, and? Epidemiology and; Prevention;, Circulation 2003 Oct 28; 108(17):2154-69.
Schaufelberger M, Swedberg K, Koster M, et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004 Feb;25(4):300-7.
Mirtoxirovna, A. M. (2020). About the persian translation of" tarikhar-rusulvalmuluk". ACADEMICIA: An International Multidisciplinary Research Journal, 10(6), 416-419.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.















